Lucius Larotrectinib – Beli Online
Lucius Larotrectinib – Beli Online
Lucius Larotrectinib – Beli Online

Lucius Larotrectinib – Beli Online

IDR 2,549,993

500+ terjual
Harga Promo

Apotek fisik Hong Kong dengan jaminan produk asli 100%

Keunggulan Produk

In 2018, the FDA approved larotrectinib in the United States for tumors driven by NTRK1, NTRK2, or NTRK3 gene fusions. Use only as directed by a physician.

Jaminan Layanan

Pengiriman Lintas NegaraApotek ResmiDitinjau ApotekerJaminan Keaslian

Spesifikasi

Spesifikasi
100mg*30 capsules
Produsen
Lucius Pharmaceuticals
Pengiriman
Hong Kong

Stok 10000

Kategori: Brand:

Informasi Produk

Nama Inggris
Larotrectinib
Nama Generik
Larotrectinib

Spesifikasi

Spesifikasi
100mg*30 capsules
Produsen
Lucius Pharmaceuticals
Pengiriman
Hong Kong

Rincian Lengkap

Indikasi

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mekanisme Kerja

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Farmakologi

12.1 Mekanisme Kerja (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dosis dan Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Peringatan

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interaksi Obat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosis dan Penggunaan(2.5)] CYP3A4 ， ， [ Dosis dan Penggunaan(2.5)]

Efek Samping

Description [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] 6.1 ， ， ， Peringatan 444 VITRAKVI ， 62% 6 ，44% ……

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Package Insert

Ingredients

11 VITRAKVI C₂₁H₂₄F₂N₆O₆S， 526.51 g/mol， 428.44 g/mol (3S)-N-{5-[(2R)-2-(2,5- )-1- ] [1,5-a] -3- }-3- -1- ，

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Dosis dan Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Efek Samping

Description [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] 6.1 ， ， ， Peringatan 444 VITRAKVI ， 62% 6 ，44% ……

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Use in Pregnancy and Lactation

8.1 ， TRK ， Mekanisme Kerja[ (12.1)]，VITRAKVI VITRAKVI ， ， ， 100 mg 11 0.7 ， ，

Interaksi Obat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosis dan Penggunaan(2.5)] CYP3A4 ， ， [ Dosis dan Penggunaan(2.5)]

Clinical Pharmacology

12 12.1 Mekanisme Kerja (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3 TRK ， ，

Clinical Studies

14 VITRAKVI ， NTRK LOXO-TRK-14001 (NCT02122913) SCOUT (NCT02637687) NAVIGATE (NCT02576431) ， ， VITRAKVI 100 mg， 18 VITRAKVI 100 mg/m²， ， 100 mg NTRK

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Ulasan Produk (15)

Filter: All Reviews
4.8★★★★★
+o***e· 3周前
★★★★
+t***3· 1个月前
Pembelian Terverifikasi
★★★★★

Deskripsi produk

Indikasi

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mekanisme Kerja

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Farmakologi

12.1 Mekanisme Kerja (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dosis dan Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Peringatan

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interaksi Obat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosis dan Penggunaan(2.5)] CYP3A4 ， ， [ Dosis dan Penggunaan(2.5)]

Efek Samping

Description [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] 6.1 ， ， ， Peringatan 444 VITRAKVI ， 62% 6 ，44% ……

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F